According to a recent LinkedIn post from F-Prime, the firm is an investor in Immutrin, which has reportedly secured a £65 million ($87 million) Series A financing. The post highlights that the round is intended to support development of next-generation antibody therapies targeting ATTR amyloidosis, with a lead asset focused on ATTR cardiomyopathy, described as a progressive and potentially fatal heart disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests Immutrin’s approach aims to leverage the body’s immune system to actively clear amyloid deposits from affected tissues, addressing what is characterized as a long-standing unmet need in amyloidosis. For F-Prime and the listed co-investors, this early-stage capital deployment increases exposure to cardiology-focused biotech innovation and could offer significant upside if Immutrin’s lead program advances successfully through clinical development.
From an industry perspective, the post points to continued investor interest in novel mechanisms for cardiac amyloidosis, a niche but growing segment within cardiovascular therapeutics. If Immutrin’s platform demonstrates clinical efficacy and safety, it could strengthen F-Prime’s position in high-impact specialty therapeutics and potentially enhance the value of its life sciences portfolio over the medium to long term.